Vaccins à ARN messager contre le Covid-19 : piqûre de rappel [mRNA Covid vaccines: What do we know eight months after deployment]

Details

Ressource 1Request a copy Under embargo until 10/05/2023.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_CE2F5557994E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Vaccins à ARN messager contre le Covid-19 : piqûre de rappel [mRNA Covid vaccines: What do we know eight months after deployment]
Journal
Revue medicale suisse
Author(s)
Miauton A., Besson J., Muller Y., Genton B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
10/11/2021
Peer-reviewed
Oui
Volume
17
Number
758
Pages
1910-1914
Language
french
Notes
Publication types: Journal Article
Publication Status: publish
Abstract
This paper summarizes the main knowledge on mRNA vaccines in September 2021. The only contraindication for a 1st dose of vaccine is an allergy to one of the components of the vaccine, but a specialized consultation is possible for an eventual split vaccination under medical supervision. Serious side effects are rare and consist mainly of myocarditis, shingles and appendicitis, but the risk/benefit ratio is always favorable for vaccination. Efficacy against severe COVID-19 is > 90 % after 6 months, and this against all variants. It is recommended to vaccinate pregnant women. A 3rd dose is not recommended at this time, except for immunosuppressed individuals without detectable antibodies after 2 doses. Vaccine mixing is possible, including with a viral vector vaccine.
Keywords
COVID-19/prevention & control, COVID-19 Vaccines, Female, Humans, Pregnancy, RNA, Messenger, Vaccination, Vaccines, Synthetic
Pubmed
Create date
15/11/2021 17:13
Last modification date
21/11/2022 8:28
Usage data